Compare Fortinet Inc (FTNT) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fortinet Inc vs BIO-TECHNE Corp — how do they compare? Fortinet Inc trades at $161.08 (market cap $120.53B), while BIO-TECHNE Corp trades at $71.63 (market cap $11.14B). The key difference: Fortinet Inc is far larger — about 10.8× BIO-TECHNE Corp's market cap, and BIO-TECHNE Corp pays a 0.45% dividend while Fortinet Inc pays none. Which is the better fit depends on your goals.
| FTNT | TECH | |
|---|---|---|
Market Cap | $120.53B | $11.14B |
Sector | Technology | Health |
52-Week High | $166.83 | $71.48 |
52-Week Low | $74.39 | $43.31 |
Enterprise Value | $117.73B | $11.22B |
Dividend Yield | — | 0.45% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Fortinet (FTNT) trades at $166.83, up 3.87% today, with a bullish technical signal from moving averages and strong quarterly earnings beats. Revenue grew to $6.80B in 2025, with a net income margin of 27.49%, though valuation ratios like P/E of 63.76 and P/S of 17.5 appear elevated. Recent news highlights AI-driven cybersecurity demand as a growth catalyst, with the company expanding its FortiEndpoint platform for AI security.
The outlook is positive due to robust earnings performance and sector tailwinds, but high valuations and competitive pressures pose risks. Analyst consensus is mixed with 42.65% buy ratings, yet the consensus price target of $123.16 suggests caution relative to the current price, indicating potential overvaluation concerns amid growth optimism.
Bio-Techne Corporation (TECH) trades at $71.66, near its all-time high, following Merck KGaA's announced $73 per share cash acquisition offer, representing a 24% premium. The stock shows a bullish technical trend, while fundamental metrics reveal a high valuation with a P/E of 102.12 and a net income margin of 9.05%. Recent earnings have been mixed, with Q4 2025 beating expectations but Q1 2026 missing. Analyst consensus is evenly split between Buy and Hold, with a $67.75 price target below the current offer price.
The investment outlook is dominated by the pending acquisition by Merck KGaA. The primary opportunity is the realization of the $73 per share offer, providing a clear exit near current levels. Key risks include potential deal completion delays, regulatory scrutiny, and shareholder litigation questioning the fairness of the price. Should the deal fall through, the stock faces significant downside pressure given its stretched valuation and recent earnings volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Fortinet Inc
Fortinet is a cybersecurity vendor that sells products, support, and services to small and midsize businesses, enterprises, and government entities. Its products include unified threat management appliances, firewalls, network security, and its security platform, Security Fabric. Services revenue is primarily from FortiGuard security subscriptions and FortiCare technical support. At the end of 2021, products were 38% of revenue and services were 62% of sales. The California-based company sells products worldwide.
Read more on FTNT →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
